(Reuters) - Shares in Ranbaxy Laboratories Ltd(RANB.NS) fell over 3 percent after the drugmaker posted losses for a second straight quarter on Tuesday, hurt by foreign exchange charges and a one-time write-off related to one of its plants under an import ban by the U.S. health regulator.
Net loss in July-September was 4.5 billion rupees compared with a profit of 7.5 billion rupees a year earlier, it said on Tuesday.
At 9:25 a.m., Ranbaxy was trading 4.4 percent lower at 368 rupees.
No comments:
Post a Comment